Esperion Therapeutics (ESPR) Enterprise Value (2012 - 2026)
Esperion Therapeutics (ESPR) posted Enterprise Value of -$156.2 million for Q1 2026, up 6.97% on a QoQ basis from -$167.9 million in Q4 2025, and down 36.22% year-over-year from -$244.9 million in Q1 2025.
Esperion Therapeutics (ESPR) Enterprise Value (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Enterprise Value history runs 15 years deep, the most recent figure standing at -$156.2 million for Q1 2026.
- Quarterly Enterprise Value fell 36.22% year-over-year to -$156.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$156.2 million (down 36.22% YoY) and the FY2025 annual result came in at -$167.9 million, down 15.95% from the prior year.
- Enterprise Value was -$156.2 million for Q1 2026 at Esperion Therapeutics, up from -$167.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$82.2 million in Q4 2023 and bottomed at -$226.6 million in Q1 2024.
- A 5-year average of -$151.8 million and a median of -$156.2 million in 2026 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 82.63% — and 2025, when it soared 54.54%.
- Esperion Therapeutics' Enterprise Value stood at -$166.9 million in 2022, then soared by 50.71% to -$82.2 million in 2023, then tumbled by 76.01% to -$144.8 million in 2024, then dropped by 15.95% to -$167.9 million in 2025, then grew by 6.97% to -$156.2 million in 2026.
- Business Quant data shows ESPR's Enterprise Value at -$156.2 million in Q1 2026, -$167.9 million in Q4 2025, and -$92.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -4.05 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -428.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -156.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -156.16 Mn |
| Dec 31, 2025 | -167.85 Mn |
| Sep 30, 2025 | -92.45 Mn |
| Jun 30, 2025 | -86.06 Mn |
| Mar 31, 2025 | -114.63 Mn |
| Dec 31, 2024 | -144.76 Mn |
| Sep 30, 2024 | -144.72 Mn |
| Jun 30, 2024 | -189.30 Mn |
| Mar 31, 2024 | -226.61 Mn |
| Dec 31, 2023 | -82.25 Mn |
| Sep 30, 2023 | -114.83 Mn |
| Jun 30, 2023 | -138.47 Mn |
| Mar 31, 2023 | -162.34 Mn |
| Dec 31, 2022 | -166.86 Mn |
| Sep 30, 2022 | -189.34 Mn |
| Jun 30, 2022 | -185.85 Mn |
| Mar 31, 2022 | -218.50 Mn |
| Dec 31, 2021 | -259.33 Mn |
| Sep 30, 2021 | -103.67 Mn |
| Jun 30, 2021 | -219.19 Mn |